SCHEMBL3530147

SCHEMBL3530147

COC(=O)CCC#Cc1cc(Cl)ccc1NS(=O)(=O)c1c(C)cc(C)cc1C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYTH2 Q99418 1/20 0.43
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
ACLY P53396 1/20 0.39
CCR9 P51686 2/20 0.39
POLB P06746 2/20 0.38
ALDH1A1 P00352 2/20 0.38
MAPT P10636 2/20 0.37
PTGDR2 Q9Y5Y4 2/20 0.37
RAB9A P51151 1/20 0.37
KEAP1 Q14145 1/20 0.37
NFE2L2 Q16236 1/20 0.37
TP53 P04637 1/20 0.37
TSHR P16473 3/20 0.37
GAA P10253 1/20 0.37
GFER P55789 1/20 0.37
LMNA P02545 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
FABP4 P15090 1/20 0.37
MCOLN3 Q8TDD5 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3529261 0.89 CCR9 (0.43) KMT2AACLYCCR9ALDH1A1MAPT
SCHEMBL3527669 0.87 LMNA (0.48) KMT2ACCR9ALDH1A1MAPTTP53
SCHEMBL3525803 0.85 ALDH1A1 (0.48) MEN1KMT2ACCR9ALDH1A1MAPT
SCHEMBL3522957 0.84 FLT1 (0.43) KMT2ACCR9ALDH1A1MAPTRAB9A
SCHEMBL3525865 0.84 CCR2 (0.48) MEN1KMT2AACLYCCR9ALDH1A1
SCHEMBL3524537 0.83 ACLY (0.47) ACLYMAPTPTGDR2TSHR
SCHEMBL3523698 0.83 ERBB2 (0.50) MEN1KMT2AACLYCCR9ALDH1A1
SCHEMBL3523112 0.83 CCR9 (0.42) KMT2AACLYCCR9MAPTTP53
SCHEMBL3524514 0.82 HSD17B2 (0.53) CCR9
SCHEMBL3524342 0.82 SLC16A3 (0.42) MEN1KMT2AACLYCCR9POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436040-B2 Method of treating conditions involving PPAR-receptors with indole compounds LABORATOIRES FOURNIER S.A. (FR) 2013-05-07 US disclosed
US-20100286137-A1 Method of Treating Conditions Involving PPAR-Receptors with Indole Compounds LABORATORIES FOURNIER S.A. (FR) 2010-11-11 US disclosed
US-7795297-B2 Indole compounds, method of preparing them and uses thereof LABORATORIES FOURNIER S.A. (FR) 2010-09-14 US disclosed
US-20080153816-A1 Indole Compounds, Method of Preparing Them and Uses Thereof LABORATOIRES FOURNIER S.A. (FR) 2008-06-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080153816-A1 Indole Compounds, Method of Preparing Them and Uses Thereof LIPG, GPR119, IAPP CYTH2 3652/4885MEN1 2711/4885KMT2A 2305/4885
US-20100286137-A1 Method of Treating Conditions Involving PPAR-Receptors with Indole Compounds GPR119, PPARA, PPARG CYTH2 3473/4885MEN1 4787/4885KMT2A 2990/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.